The promise of epigenomic therapeutics in pancreatic cancer

Gwen A. Lomberk, Juan Iovanna, Raul Urrutia

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.

Original languageEnglish (US)
Pages (from-to)831-842
Number of pages12
Issue number6
StatePublished - Jun 2016


  • DNA methylation
  • DNMTs
  • HATs
  • HDACs
  • HMTs
  • chromatin
  • epigenetics
  • noncoding RNAs
  • pancreatic cancer
  • therapeutics

ASJC Scopus subject areas

  • Genetics
  • Cancer Research


Dive into the research topics of 'The promise of epigenomic therapeutics in pancreatic cancer'. Together they form a unique fingerprint.

Cite this